Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy

16 Aug 2013

Abstract excerpt

Metastatic melanoma remains a mostly incurable disease. Although newly approved targeted therapies are efficacious in a subset of patients, resistance and relapse rapidly ensue. Alternative therapeutic strategies to manipulate epigenetic regulators and disrupt the transcriptional program that maintains tumor cell identity are emerging. Bromodomain and extraterminal domain (BET) proteins are epigenome readers...

Topics

Join the communities discussing this publication.

Histone Deacetylase Inhibitors Research
Multiple Myeloma Research and Treatments
Protein Degradation and Inhibitors

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 23950209
DOI: 10.1158/0008-5472.can-13-0122-t

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic TherapyPMID 23950209Read ↗

The BRD9/7 Inhibitor TP-472 Blocks Melanoma Tumor Growth by Suppressing ECM-Mediated Oncogenic Signaling and Inducing ApoptosisSemantic proximity Read ↗

BRD4 and Cancer: going beyond transcriptional regulationSemantic proximity Read ↗

BET inhibitor in combination with BCG vaccine enhances antitumor efficacy and orchestrates T cell reprogramming for melanomaSemantic proximity Read ↗

Identification of targetable epigenetic vulnerabilities for uveal melanomaSemantic proximity Read ↗

BRN2 is a non-canonical melanoma tumor-suppressorSemantic proximity Read ↗

Bromodomain-Containing Protein BRD4 Is Hyperphosphorylated in MitosisSemantic proximity Read ↗

The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.Semantic proximity Read ↗

Targeting BET Bromodomains for Cancer TreatmentSemantic proximity Read ↗

Post-Translational Modifications of BRD4: Therapeutic Targets for TumorSemantic proximity Read ↗

Inhibition of NF-κB–Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal MelanomaSemantic proximity Read ↗

The epigenetic regulator TRIM24 controls melanoma cell dedifferentiation and resistance to treatment in melanomaSemantic proximity Read ↗

Bromodomain protein BRD4 directs and sustains CD8 T cell differentiation during infectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.